By Ed Coghlan.
Migraine and headache specialists from around the world are attending the American Headache Society (AHS) 60th Annual Scientific Meeting in San Francisco.
There are a number of late breaking studies being reviewed this weekend.
Among them are findings on investigational treatments for cluster headache and migraine including those targeting calcitonin gene-related peptide (CGRP) mechanisms and neuromodulation; work on medication overuse headache in association with adverse childhood experiences; and distinguishing brain nerve-fiber profiles in patients with migraine and post-traumatic headaches.
“These studies bring us closer to realizing the potential of novel therapies for those in substantial need,” said Peter Goadsby, MD, PhD, FAHS, AHS Scientific Program Committee Chair, Professor of Neurology at King’s College, London and University of California, San Francisco and Director of NIHR-Wellcome Trust Clinical Research Facility, King’s College Hospital, London. “The American Headache Society has been at the forefront of improving the understanding of migraine and other types of headache, and we thank the patients who participated in the studies, as well as the physicians that contributed to these important studies.”
Migraine is a major disabling neurological disease that affects more than over 37 million men, women and children in the United States. The disease impacts one in four households, one in five women, one in 16 men and one in 11 children in the United States. Globally, migraine is the sixth highest cause of years of life lost due to disability. Individuals who experience migraine have symptoms that include nausea, sensitivity to light and/or odors, skin sensitivity, fatigue, mood change, dizziness, difficulty concentrating, neck pain and changes in vision, including seeing spots, stars, lines, flashing lights and zigzag lines. The risk of other serious diseases is significantly higher in those with migraine, including stroke, epilepsy, depression, anxiety and chronic pain. Despite this, only one of every three people talk with a doctor about their migraine attacks and of those, only half get the right diagnosis. There is also a massive shortage of specialists focusing on migraine, with one specialist for every 65,000 individuals living with migraine, which worsens the problem.
The American Headache Society (AHS) is a professional society of health care providers dedicated to the study and treatment of headache and face pain. The Society’s objectives are to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals and the public and encouraging scientific research are the primary functions of this organization. AHS activities include an annual scientific meeting, a comprehensive headache symposium, regional symposia for neurologists and family practice physicians, and publication of the journal Headache. More information can be found at www.americanheadachesociety.org.
In 2010, AHS founded the American Migraine Foundation (AMF) to provide access to information and resources for individuals living with migraine, as well as their loved ones. AMF is a non-profit organization dedicated to the advancement of research and awareness surrounding migraine.